Darbepoetin alfa

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Analog of human erythropoietin.

Pharmacodynamics (Effect)
This section has been translated automatically.

Stimulation of the proliferation and differentiation of erythrocyte precursors.

Indication
This section has been translated automatically.

Anemia in chronic renal failure in adults and children ≥ 11 LJ. For the treatment of symptomatic anaemia in adult tumour patients with non-myeloidal malignant diseases receiving chemotherapy.

Dosage and method of use
This section has been translated automatically.

For symptomatic, chemotherapy-induced anemia in tumor patients (e.g., hemoglobin concentration < 10 g/dl [6.2 mmol/l]) to increase the hemoglobin value to a maximum of 12 g/dl (7.5 mmol/l): Initial once 3 times a week 500 μg s.c. (6.75 μg/kg bw). Alternatively: once a week 2,25 μg/kg KG. If necessary, dose adjustment during weekly Hb controls.

Undesirable effects
This section has been translated automatically.

Headaches, high blood pressure, thrombosis of the vascular access and pain and local reactions at the injection site

Preparations
This section has been translated automatically.

Aranesp

Authors

Last updated on: 29.10.2020